Notably, IL-6 treatment activated the STAT3/Notch pathway and increased cell resistance to DDP, whereas GA interfered with the impact of IL-6 treatment, confirming that GA enhanced the DDP sensitivity of ESCC cells by inhibiting IL-6/STAT3/Notch pathway. This evidence concerns the gene STAT3 and esophageal squamous cell carcinoma.